The BCL-2 inhibitor genetical has demonstrated remarkable synergy with hypomethylating agents in acute myeloid leukemia (AML), leading to its adoption as first-line therapy for older patients [7]. The gene discussed is BCL2; the disease is acute myeloid leukemia.